Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT)

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT)
Recruiting
12 years - 99 years
All
Phase 3
75 participants needed
1 Location

Brief description of study

The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S. aureus) bloodstream infections (BSI), including right-sided infective endocarditis (IE). Patients will be randomized to receive a single intravenous dose of exebacase or placebo. Patients will receive SoCA selected by the investigators based on the protocol.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: S. aureus bloodstream infection,S. aureus bacteremia,S. aureus right-sided infective endocarditis
  • Age: 12 years - 99 years
  • Gender: All

Male or female, 12 years or older, Blood culture positive for S. aureus, two signs or symptoms attributable to S. aureus BSI/IE

Online study
Updated on 20 Feb 2025. Study ID: 843298

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center